Do analysts prefer LEXX or EXOZ?

Lexaria Bioscience presently has a consensus price target of $1.50, suggesting a potential upside of 124.55%. Given Lexaria Bioscience's stronger consensus rating and higher probable upside, analysts clearly believe Lexaria Bioscience is more favorable than eXoZymes. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Lexaria Bioscience 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 eXoZymes 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Is LEXX or EXOZ more profitable?

Lexaria Bioscience's return on equity of -206.02% beat eXoZymes' return on equity. Company Net Margins Return on Equity Return on Assets Lexaria Bioscience N/A -206.02% -162.53% eXoZymes N/A -220.63% -141.26%

Is CING or LEXX more profitable?

Lexaria Bioscience's return on equity of -206.02% beat Cingulate's return on equity. Company Net Margins Return on Equity Return on Assets Cingulate N/A -365.15% -158.55% Lexaria Bioscience N/A -206.02% -162.53%

Is UPXI or LEXX more profitable?

Lexaria Bioscience has a net margin of 0.00% compared to Upexi's net margin of -874.00%. Upexi's return on equity of -66.70% beat Lexaria Bioscience's return on equity. Company Net Margins Return on Equity Return on Assets Upexi -874.00% -66.70% -19.56% Lexaria Bioscience N/A -206.02% -162.53%

Lexaria Bioscience (LEXX) Competitors

$0.67 +0.02 (+3.31%)

Closing price 04:00 PM Eastern

Extended Trading

$0.70 +0.03 (+4.79%)

As of 07:32 PM Eastern

Compare

LEXX vs. EXOZ, TCRX, CING, UPXI, and MNOV

Should you buy Lexaria Bioscience stock or one of its competitors? MarketBeat compares Lexaria Bioscience with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Lexaria Bioscience include eXoZymes (EXOZ), TScan Therapeutics (TCRX), Cingulate (CING), Upexi (UPXI), and MediciNova (MNOV). These companies are all part of the "pharmaceutical products" industry.

How does Lexaria Bioscience compare to eXoZymes?

Lexaria Bioscience (NASDAQ:LEXX) and eXoZymes (NASDAQ:EXOZ) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their dividends, media sentiment, risk, earnings, institutional ownership, analyst recommendations, valuation and profitability.

Lexaria Bioscience presently has a consensus price target of $1.50, suggesting a potential upside of 124.55%. Given Lexaria Bioscience's stronger consensus rating and higher probable upside, analysts clearly believe Lexaria Bioscience is more favorable than eXoZymes.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Lexaria Bioscience	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
eXoZymes	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Lexaria Bioscience's return on equity of -206.02% beat eXoZymes' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Lexaria Bioscience	N/A	-206.02%	-162.53%
eXoZymes	N/A	-220.63%	-141.26%

Lexaria Bioscience has a beta of 0.35, suggesting that its share price is 65% less volatile than the broader market. Comparatively, eXoZymes has a beta of 2.65, suggesting that its share price is 165% more volatile than the broader market.

eXoZymes has lower revenue, but higher earnings than Lexaria Bioscience. eXoZymes is trading at a lower price-to-earnings ratio than Lexaria Bioscience, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Lexaria Bioscience	$710K	23.32	-$11.90M	-$0.47	N/A
eXoZymes	$70K	944.91	-$9.16M	-$1.14	N/A

In the previous week, eXoZymes had 1 more articles in the media than Lexaria Bioscience. MarketBeat recorded 2 mentions for eXoZymes and 1 mentions for Lexaria Bioscience. eXoZymes' average media sentiment score of 0.98 beat Lexaria Bioscience's score of 0.37 indicating that eXoZymes is being referred to more favorably in the news media.

Company	Overall Sentiment
Lexaria Bioscience	Neutral
eXoZymes	Positive

13.1% of Lexaria Bioscience shares are held by institutional investors. 8.4% of Lexaria Bioscience shares are held by insiders. Comparatively, 72.4% of eXoZymes shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Summary

Lexaria Bioscience beats eXoZymes on 8 of the 15 factors compared between the two stocks.

How does Lexaria Bioscience compare to TScan Therapeutics?

TScan Therapeutics (NASDAQ:TCRX) and Lexaria Bioscience (NASDAQ:LEXX) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, media sentiment, risk, valuation, institutional ownership, earnings, analyst recommendations and profitability.

In the previous week, TScan Therapeutics had 1 more articles in the media than Lexaria Bioscience. MarketBeat recorded 2 mentions for TScan Therapeutics and 1 mentions for Lexaria Bioscience. TScan Therapeutics' average media sentiment score of 1.18 beat Lexaria Bioscience's score of 0.37 indicating that TScan Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
TScan Therapeutics	Positive
Lexaria Bioscience	Neutral

TScan Therapeutics has a beta of 1.03, suggesting that its stock price is 3% more volatile than the broader market. Comparatively, Lexaria Bioscience has a beta of 0.35, suggesting that its stock price is 65% less volatile than the broader market.

Lexaria Bioscience has lower revenue, but higher earnings than TScan Therapeutics. Lexaria Bioscience is trading at a lower price-to-earnings ratio than TScan Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
TScan Therapeutics	$10.32M	6.11	-$129.77M	-$0.96	N/A
Lexaria Bioscience	$710K	23.32	-$11.90M	-$0.47	N/A

82.8% of TScan Therapeutics shares are held by institutional investors. Comparatively, 13.1% of Lexaria Bioscience shares are held by institutional investors. 6.3% of TScan Therapeutics shares are held by insiders. Comparatively, 8.4% of Lexaria Bioscience shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Lexaria Bioscience has a net margin of 0.00% compared to TScan Therapeutics' net margin of -1,360.61%. TScan Therapeutics' return on equity of -91.94% beat Lexaria Bioscience's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
TScan Therapeutics	-1,360.61%	-91.94%	-50.15%
Lexaria Bioscience	N/A	-206.02%	-162.53%

TScan Therapeutics presently has a consensus price target of $6.00, suggesting a potential upside of 521.44%. Lexaria Bioscience has a consensus price target of $1.50, suggesting a potential upside of 124.55%. Given TScan Therapeutics' stronger consensus rating and higher possible upside, equities research analysts clearly believe TScan Therapeutics is more favorable than Lexaria Bioscience.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
TScan Therapeutics	1 Sell rating(s)	2 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.33
Lexaria Bioscience	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Summary

TScan Therapeutics beats Lexaria Bioscience on 11 of the 16 factors compared between the two stocks.

How does Lexaria Bioscience compare to Cingulate?

Cingulate (NASDAQ:CING) and Lexaria Bioscience (NASDAQ:LEXX) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their profitability, earnings, analyst recommendations, valuation, institutional ownership, dividends, risk and media sentiment.

In the previous week, Cingulate had 7 more articles in the media than Lexaria Bioscience. MarketBeat recorded 8 mentions for Cingulate and 1 mentions for Lexaria Bioscience. Lexaria Bioscience's average media sentiment score of 0.37 beat Cingulate's score of 0.26 indicating that Lexaria Bioscience is being referred to more favorably in the news media.

Company	Overall Sentiment
Cingulate	Neutral
Lexaria Bioscience	Neutral

Cingulate has a beta of -0.85, indicating that its stock price is 185% less volatile than the broader market. Comparatively, Lexaria Bioscience has a beta of 0.35, indicating that its stock price is 65% less volatile than the broader market.

41.3% of Cingulate shares are owned by institutional investors. Comparatively, 13.1% of Lexaria Bioscience shares are owned by institutional investors. 5.3% of Cingulate shares are owned by company insiders. Comparatively, 8.4% of Lexaria Bioscience shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Lexaria Bioscience has higher revenue and earnings than Cingulate. Lexaria Bioscience is trading at a lower price-to-earnings ratio than Cingulate, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cingulate	N/A	N/A	-$22.45M	-$4.23	N/A
Lexaria Bioscience	$710K	23.32	-$11.90M	-$0.47	N/A

Cingulate presently has a consensus price target of $27.33, indicating a potential upside of 487.81%. Lexaria Bioscience has a consensus price target of $1.50, indicating a potential upside of 124.55%. Given Cingulate's stronger consensus rating and higher probable upside, research analysts plainly believe Cingulate is more favorable than Lexaria Bioscience.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cingulate	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50
Lexaria Bioscience	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Lexaria Bioscience's return on equity of -206.02% beat Cingulate's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cingulate	N/A	-365.15%	-158.55%
Lexaria Bioscience	N/A	-206.02%	-162.53%

Summary

Cingulate and Lexaria Bioscience tied by winning 7 of the 14 factors compared between the two stocks.

How does Lexaria Bioscience compare to Upexi?

Upexi (NASDAQ:UPXI) and Lexaria Bioscience (NASDAQ:LEXX) are both small-cap pharmaceutical products companies, but which is the superior investment? We will contrast the two businesses based on the strength of their media sentiment, institutional ownership, risk, dividends, analyst recommendations, profitability, earnings and valuation.

Upexi has a beta of -0.35, meaning that its share price is 135% less volatile than the broader market. Comparatively, Lexaria Bioscience has a beta of 0.35, meaning that its share price is 65% less volatile than the broader market.

5.7% of Upexi shares are owned by institutional investors. Comparatively, 13.1% of Lexaria Bioscience shares are owned by institutional investors. 9.0% of Upexi shares are owned by company insiders. Comparatively, 8.4% of Lexaria Bioscience shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Lexaria Bioscience has a net margin of 0.00% compared to Upexi's net margin of -874.00%. Upexi's return on equity of -66.70% beat Lexaria Bioscience's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Upexi	-874.00%	-66.70%	-19.56%
Lexaria Bioscience	N/A	-206.02%	-162.53%

Upexi presently has a consensus target price of $8.33, indicating a potential upside of 835.28%. Lexaria Bioscience has a consensus target price of $1.50, indicating a potential upside of 124.55%. Given Upexi's stronger consensus rating and higher probable upside, analysts plainly believe Upexi is more favorable than Lexaria Bioscience.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Upexi	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.67
Lexaria Bioscience	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Lexaria Bioscience has lower revenue, but higher earnings than Upexi. Upexi is trading at a lower price-to-earnings ratio than Lexaria Bioscience, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Upexi	$15.81M	3.96	-$13.68M	-$0.62	N/A
Lexaria Bioscience	$710K	23.32	-$11.90M	-$0.47	N/A

In the previous week, Upexi and Upexi both had 1 articles in the media. Upexi's average media sentiment score of 1.87 beat Lexaria Bioscience's score of 0.37 indicating that Upexi is being referred to more favorably in the media.

Company	Overall Sentiment
Upexi	Very Positive
Lexaria Bioscience	Neutral

Summary

Upexi beats Lexaria Bioscience on 8 of the 15 factors compared between the two stocks.

How does Lexaria Bioscience compare to MediciNova?

MediciNova (NASDAQ:MNOV) and Lexaria Bioscience (NASDAQ:LEXX) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their profitability, valuation, earnings, analyst recommendations, risk, institutional ownership, media sentiment and dividends.

MediciNova presently has a consensus price target of $7.50, suggesting a potential upside of 490.55%. Lexaria Bioscience has a consensus price target of $1.50, suggesting a potential upside of 124.55%. Given MediciNova's stronger consensus rating and higher possible upside, analysts clearly believe MediciNova is more favorable than Lexaria Bioscience.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
MediciNova	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	2 Strong Buy rating(s)	2.86
Lexaria Bioscience	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Lexaria Bioscience has a net margin of 0.00% compared to MediciNova's net margin of -1,962.98%. MediciNova's return on equity of -27.28% beat Lexaria Bioscience's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
MediciNova	-1,962.98%	-27.28%	-25.24%
Lexaria Bioscience	N/A	-206.02%	-162.53%

MediciNova has a beta of 0.62, indicating that its share price is 38% less volatile than the broader market. Comparatively, Lexaria Bioscience has a beta of 0.35, indicating that its share price is 65% less volatile than the broader market.

In the previous week, MediciNova had 3 more articles in the media than Lexaria Bioscience. MarketBeat recorded 4 mentions for MediciNova and 1 mentions for Lexaria Bioscience. MediciNova's average media sentiment score of 0.58 beat Lexaria Bioscience's score of 0.37 indicating that MediciNova is being referred to more favorably in the media.

Company	Overall Sentiment
MediciNova	Positive
Lexaria Bioscience	Neutral

9.9% of MediciNova shares are held by institutional investors. Comparatively, 13.1% of Lexaria Bioscience shares are held by institutional investors. 14.0% of MediciNova shares are held by company insiders. Comparatively, 8.4% of Lexaria Bioscience shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Lexaria Bioscience has higher revenue and earnings than MediciNova. MediciNova is trading at a lower price-to-earnings ratio than Lexaria Bioscience, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
MediciNova	$410K	152.46	-$12M	-$0.23	N/A
Lexaria Bioscience	$710K	23.32	-$11.90M	-$0.47	N/A

Summary

MediciNova beats Lexaria Bioscience on 12 of the 17 factors compared between the two stocks.

Get Lexaria Bioscience News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding LEXX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

LEXX vs. The Competition

Export

Metric	Lexaria Bioscience	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$16.03M	$3.30B	$6.64B	$12.06B
Dividend Yield	N/A	2.33%	2.67%	5.55%
P/E Ratio	-1.42	18.68	24.75	23.76
Price / Sales	23.32	297.55	508.64	105.22
Price / Cash	N/A	118.24	42.36	56.09
Price / Book	5.14	8.06	10.47	6.72
Net Income	-$11.90M	$23.83M	$3.56B	$337.35M
7 Day Performance	11.15%	-2.82%	-1.11%	-2.54%
1 Month Performance	9.54%	2.22%	1.28%	1.42%
1 Year Performance	-33.20%	37.70%	21.20%	24.71%

Lexaria Bioscience Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
LEXX Lexaria Bioscience	2.2495 of 5 stars	$0.67 +3.3%	$1.50 +124.6%	-34.4%	$16.03M	$710K	N/A	7	News Coverage Gap Up
EXOZ eXoZymes	0.7128 of 5 stars	$7.80 -9.5%	N/A	-35.9%	$66.14M	$70K	N/A	29	News Coverage Gap Down High Trading Volume
TCRX TScan Therapeutics	3.2508 of 5 stars	$0.97 -2.9%	$6.00 +521.4%	-44.8%	$63.10M	$9.14M	N/A	100	Positive News
CING Cingulate	3.0815 of 5 stars	$4.65 +2.6%	$27.33 +487.8%	+3.9%	$62.63M	N/A	N/A	20	News Coverage Analyst Forecast Insider Trade Gap Up
UPXI Upexi	2.8 of 5 stars	$0.89 -6.2%	$8.33 +835.3%	-91.5%	$62.60M	$26.14M	N/A	130	Positive News Analyst Downgrade

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:LEXX) was last updated on 6/9/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Lexaria Bioscience (LEXX) Competitors

LEXX vs. EXOZ, TCRX, CING, UPXI, and MNOV

How does Lexaria Bioscience compare to eXoZymes?

Summary

How does Lexaria Bioscience compare to TScan Therapeutics?

Summary

How does Lexaria Bioscience compare to Cingulate?

Summary

How does Lexaria Bioscience compare to Upexi?

Summary

How does Lexaria Bioscience compare to MediciNova?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

LEXX vs. The Competition

Lexaria Bioscience Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Lexaria Bioscience (LEXX) Competitors

LEXX vs. EXOZ, TCRX, CING, UPXI, and MNOV

How does Lexaria Bioscience compare to eXoZymes?

Do analysts prefer LEXX or EXOZ?

Is LEXX or EXOZ more profitable?

Which has more risk and volatility, LEXX or EXOZ?

Which has better earnings and valuation, LEXX or EXOZ?

Does the media prefer LEXX or EXOZ?

Do insiders and institutionals hold more shares of LEXX or EXOZ?

Summary

How does Lexaria Bioscience compare to TScan Therapeutics?

Does the media favor TCRX or LEXX?

Which has more volatility & risk, TCRX or LEXX?

Which has preferable valuation & earnings, TCRX or LEXX?

Do institutionals and insiders hold more shares of TCRX or LEXX?

Is TCRX or LEXX more profitable?

Do analysts prefer TCRX or LEXX?

Summary

How does Lexaria Bioscience compare to Cingulate?

Does the media prefer CING or LEXX?

Which has more risk and volatility, CING or LEXX?

Do insiders & institutionals have more ownership in CING or LEXX?

Which has stronger valuation & earnings, CING or LEXX?

Do analysts recommend CING or LEXX?

Is CING or LEXX more profitable?

Summary

How does Lexaria Bioscience compare to Upexi?

Which has more risk & volatility, UPXI or LEXX?

Do institutionals and insiders believe in UPXI or LEXX?

Is UPXI or LEXX more profitable?

Do analysts rate UPXI or LEXX?

Which has higher earnings and valuation, UPXI or LEXX?

Does the media favor UPXI or LEXX?

Summary

How does Lexaria Bioscience compare to MediciNova?

Do analysts recommend MNOV or LEXX?

Is MNOV or LEXX more profitable?

Which has more risk & volatility, MNOV or LEXX?

Does the media favor MNOV or LEXX?

Do institutionals & insiders hold more shares of MNOV or LEXX?

Which has preferable valuation and earnings, MNOV or LEXX?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

LEXX vs. The Competition

Lexaria Bioscience Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools